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In partial monosomy of the distal part of chromosome 16q, abnormal facial 
features, intellectual disability (ID), and feeding dysfunction are often reported. 
However, seizures are not typical and the majority of them were seizure-free. 
Here we present the case of a 16q22.2-q23.1 interstitial deletion identified in a 
male patient with severe ID, facial anomalies including forehead protrusions and 
flat nose bridge, patent ductus arteriosus, bilateral vocal cord atresia treated by 
tracheotomy, and West syndrome, which were developed 10 months after birth. 
Although phenobarbital, sodium valproate (VPA), and zonisamide were not 
effective as monotherapies or combination therapies, the patient's epileptic 
seizures and electroencephalogram anomalies disappeared following combined 
therapy with lamotrigine and VPA. Although WW Domain Containing 
Oxidoreductase (WWOX), which is known as a cause of autosomal recessive 
epileptic encephalopathy, was included within the 6.8-Mb deleted region which 
identified by targeted panel sequencing and validated by chromosomal 
microarray analysis, no pathogenic variants were detected in the other allele of 
WWOX. Therefore, it is possible that other genes within or outside of the long 
deleted region or their interactions may cause West syndrome in this patient. 
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Chromosome 16 deletion is a rare genetic condition in which genetic material is 
missing from chromosome 16, one of the body's 46 chromosomes. In 
chromosome 16 deletion cases, the likelihood and severity of problems depend 
on which regions of the chromosome are missing. In a study of 13 patients with 
distal interstitial deletions between 16q21 and 16q24, abnormal facial features, 
intellectual disability (ID), and feeding dysfunction were commonly reported [1]. 
However, those cases did not include any indication of epilepsy.  
In this report, we describe the case of a Japanese boy who presented 
West syndrome and interstitial 16q22.2-q23.1 deletion. The patient did not 
respond to various antiepileptic drugs, but eventually responded to a combined 
treatment with lamotrigine (LTG) and sodium valproate (VPA). 
 
Case report 
A 4-year and 7-month-old Japanese male was the first child of 
non-consanguineous, healthy parents who had no notable family disease history. 
The patient was born at 38 weeks of gestation with a birth weight of 2508 g, body 
height of 49 cm (+0.2 SD), and head circumference of 31 cm (−1.6 SD). The 
patient exhibited severe developmental delay from birth. He began to gain head 
and neck stability at 8 months of age and rolled over at 1 year and 10 months of 
age. And several facial anomalies including forehead protrusions, a flat nose 
bridge, and low-set ears were observed (Figure 1). Patent ductus arteriosus 
(PDA) was also detected in the patient. Consequently, catheter embolization of 
PDA was performed at 3 years old.  After endotracheal intubation and artificial 
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ventilation due to respiratory syncytial virus infection, bilateral vocal cord atresia 
occurred. Tracheostomy was performed to enable respiration. Conventional 
chromosome analysis revealed a normal male karyotype of 46,XY, and all 
subtelomeric fluorescence in situ hybridization tests revealed normal patterns. At 
10 months old, the patient's mother observed periodic abnormal activity in his 
upper limbs immediately after waking, but the observation was not considered 
serious. At 1 year and 4 months of age, the patient's mother consulted an 
attending doctor regarding this periodic symptom. The patient was diagnosed 
with West syndrome based on serial spasms observed in a video of the patient's 
motor activity and hypsarrhythmia recorded by electroencephalogram (EEG) 
(Figure 2A). A slight cisternal expansion was observed in the brain magnetic 
resonance imaging; however, no further abnormal findings were noted. 
Considering the patient's severe inborn ID and tracheostomy, we concluded that 
treatment with antiepileptic drugs was preferable to adrenocorticotropic hormone 
(ACTH) therapy to avoid the severity of potential side effects from ACTH. 
Phenobarbital (PB) was initially administered, but its effect was insufficient. 
Several health problems must be managed, and due to the side effects of the 
rapid increase in the dosage of antiepileptics, caution must be observed when 
administering such drugs.  At 2 years and 3 months of age, PB was replaced 
with VPA, which was also insufficient. Zonisamide (ZNS) treatment was 
commenced at 2 years and 10 months of age; however, an increase in sputum 
prompted discontinuation of the treatment. At 2 years and 11 months of age, the 
EEG displayed diffuse polyspikes and polyspikes and waves (Figure 2B). 
Antiepileptic drug treatment was switched to a combination of VPA and LTG, 
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which was followed by complete disappearance of epileptic seizures. By the time 
the patient was 3 years and 5 months old, EEG abnormalities had also 
disappeared (Figure 2C).  After the recession of spasms and improvement of 
EEG abnormalities, emotional expression and sitting position stability gradually 
improved. The patient remained seizure-free at 4 years and 7 months of age, 
and he was able to feed orally, which allowed him to consume one-third of his 
daily energy needs.  
An overview of the clinical course of this case is illustrated in Figure 3. 
 
Molecular genetic analysis 
This study was performed in accordance with the Declaration of Helsinki 
Principles and was approved by the ethics committee of Tokushima University. 
Blood samples were obtained from the patient upon receiving written informed 
consent from his parents.  
 We conducted a targeted panel sequencing (TPS) for the targeted exons 
of 4813 disease-related genes using a TruSight One Sequencing Panel and 
MiSeq (Illumina, San Diego, CA, USA) with our pipeline for next-generation 
sequencing data analysis, as previously described [2,3]. The detection of copy 
number variations using TPS data with a resolution ranging from a single exon to 
several exons, depending on the exon sizes, was performed as previously 
described [2]. These analyses revealed no disease-causing single-nucleotide 
variations or small indels but did detect an interstitial gross deletion between the 
PH Domain And Leucine Rich Repeat Protein Phosphatase 2 (PHLPP2) and 
WW Domain Containing Oxidoreductase (WWOX) genes within 16q22.2-q23.1. 
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Both breakpoints of the deleted region were located within those genes. All the 
sequenced positions of 12 targeted genes located within the deleted region were 
inspected by visual verification of the alignment file using the Integrative 
Genomics Viewer (IGV) to ascertain whether the “no call’ status was due to 
insufficient coverage, any artifacts, or misalignment. Subsequent chromosomal 
microarray analysis was conducted for validation and fine mapping of the 
deleted region using an Affymetrix CytoScan HD chromosome microarray 
platform (Affymetrix, Santa Clara, CA, USA) [2]. A 6.8 Mb heterozygous 
chromosomal deletion was detected within 16q22.2-q23.1, which contains 57 
Refseq genes including PHLPP2 and WWOX, as 46,XY.arr[hg19] 
16q22.2q23.1(71,689,186-78,530,357)x1 (Supplementary Table S1).  
Parental DNA was unavailable; therefore, the deletion was not confirmed as 
occurring de novo. 
  
Discussion 
Among the genes within the 6.8 Mb interstitial 16q22.2-q23.1 deletion detected 
in the present case, WWOX and Fatty acid 2-hydroxylase (FA2H) have been 
reported as causes of epilepsy according to ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/). WWOX is a well-known cause of 
early-infantile epileptic encephalopathy 28 (EIEE28). Hussain T et al. reported 
that WWOX deletion leads to a reduction in GABAergic inhibitory interneurons, 
along with the activation of microglia and astrocytes in the mouse hippocampus 
[4]. However, all reported cases of EIEE28 show that patients with epilepsy 
present homozygous or compound heterozygous pathogenic WWOX variants 
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including deletions. Through screening cases with (1) pathogenic/likely 
pathogenic deletions overlapped with the deleted region in our case and (2) 
epileptic encephalopathy/seizures as phenotypes in the DECIPHER v9.28 
database (https://decipher.sanger.ac.uk/), we only identified two cases (#354399 
and #384984), that had the same deletion partially containing the coding exons 
of WWOX inherited from the mother and the same missense variant with 
uncertain significance, NM_016373.3:c.49G>A/p.(Glu17Lys) within the other 
allele of WWOX. In the DECIPHER database, no cases with epileptic 
encephalopathy/seizures caused by gross heterozygous deletions largely 
overlapped with the deleted region in our cases were observed. Thus, the 
relationship between haploinsufficiency of WWOX and/or other genes located 
around WWOX and West syndrome remains unclear, although only 12 of 37 
Online Mendelian Inheritance in Man (OMIM) genes were included in the 
sequencing panel used in this study (Supplementary Table S1).  
Homozygous or compound heterozygous pathogenic FA2H variants 
cause fatty acid hydroxylase-associated neurodegeneration, which is 
characterized by effects of the central nervous system including impaired 
corticospinal tract activity (spasticity), mixed movement disorders 
(ataxia/dystonia), and eye conditions (optic atrophy and oculomotor 
abnormalities) early in the disease course and by progressive intellectual 
impairment and epilepsy later in the disease course [5]. Epileptic seizures, which 
can be caused by pathogenic FA2H variants, are typically infrequent and 
respond relatively well to anticonvulsants. FA2H was included in the sequencing 
panel. However, no pathogenic variants were detected using our TPS 
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(Supplementary Table S1). Because it is possible that genes, which are not 
included in the sequencing panel used in this study, may cause West syndrome, 
further whole exome or whole genome sequencing may enable the identification 
of the candidate disease-causing genes. 
When children fail to achieve complete cessation of infantile spasms after 
treatment with ACTH or vigabatrin, or when they cannot be treated with these 
drugs, second-line medications are necessary. In uncontrolled studies, these 
medications may include topiramate, ZNS, VPA, nitrazepam, LTG, levetiracetam, 
felbamate, high-dose pyridoxine, liposteroid, ganaxolone, or 
thyrotropin-releasing hormone [6]. There are various reports that evaluate the 
efficacy of LTG in the treatment of West syndrome. In a single-blind, 
placebo-controlled, add-on study, 30 patients with infantile spasms refractory to 
conventional antiepileptic drugs and to vigabatrin and corticotropin were treated 
with LTG. Nine patients showed a >50% decrease in infantile spasms, five of 
which achieved complete cessation [7]. Additionally, three infants affected with 
symptomatic West syndrome who were unresponsive to vigabatrin and ACTH 
were successfully treated with very small doses of LTG [8].  
In this patient, changes in the EEG findings eventually suggested 
Lennox–Gastaut syndrome. Rational multidrug therapy should be considered for 
intractable epilepsy patients if surgical intervention is too difficult. Lennox–
Gastaut syndrome (LGS) is a well-defined epileptic encephalopathy that is highly 
drug resistant. The first-line treatment is valproate (VPA) combined with 
lamotrigine.[9] 
  The clinical efficacy of combined VPA and LTG therapy has been 
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previously confirmed. Brodie et al. recruited 347 patients with epilepsy that was 
not fully controlled by VPA, carbamazepine (CBZ), phenytoin (PHT), or PB 
monotherapy into an LTG substitution study [10]. The addition of LTG to VPA 
produced a significantly improved response rate (64%) compared with the 
addition of CBZ (41%) or PHT (38%). This effect was also observed in the 
treatment of partial and tonic–clonic seizures. These data provide evidence for 
the beneficial therapeutic synergy between LTG and VPA observed in our study. 
During combination therapy with antiepileptic drugs, differences between 
functional mechanisms are important factors underlying the success of treatment. 
LTG acts through voltage-sensitive sodium channels, stabilizing neural 
membranes and inhibiting the release of excitatory neurotransmitters [11]. VPA 
promotes the elevation of gamma-aminobutyric acid (GABA) levels, dopamine 
levels, and serotonin metabolism, which contributes to the activation of an 
intracerebral suppression network. These unique pharmacological attributes 
may explain the observed success of LTG + VPA therapy in West syndrome. As 
mentioned above, various genes may be associated with the cause of epilepsy 
in this patient. Our findings suggest that a combination of antiepileptic drugs with 






A male patient with an interstitial 16q22.2-q23.1 deletion presented West 
syndrome, which has never been reported as a phenotype in cases with 
deletions in this region. The patient's seizures were successfully treated with the 
combination of LTG and VPA therapies. Although WWOX is a well-known cause 
of autosomal recessive epileptic encephalopathy within the 6.8-Mb deleted 
region, no pathogenic variants were identified in this gene. Therefore, it is 
possible that other genes within or outside of the long deleted region or their 
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Figure 1. Facial appearance at 4 years and 5 months old. Several facial 
anomalies, such as forehead protrusions, flat nose bridge, and low set ears, 
were observed. We got the permission from his parents to post this photograph. 
 
Figure 2. 
A: Electroencephalogram (EEG) at 1 year and 4 months old (before treatment). 
Irregular multifocal spikes and slow waves were observed occasionally; we 
diagnosed this EEG as mild type of hypsarrhythmia.  
B: EEG before adding on lamotrigine (LTG) at 2 years and 11 months old.  
Diffuse polyspikes and polyspikes and wave were found.  
C: EEG after adding LTG at 3 years and 5 months old. The epileptic discharge 
disappeared, and sleep spindle was observed.  
 
 
Figure 3. Clinical course of the present case. 
Spasms decreased according to the increase of LTG dosage and elevation of 
LTG blood concentration. 
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PB, phenobarbital; VPA, valproic acid; ZNS, zonisamide; LTG, lamotrigine; PDA, 
patent ductus arteriosus. 
 
 
Figure 1. Facial appearance at 4 years and 5 months old. Several facial anomalies, such as forehead protrusions, flat nose bridge, 


































































A: Electroencephalogram (EEG) at 1 year 
and 4 months old (before treatment). 
Irregular multifocal spikes and slow waves 
were observed occasionally; we 
diagnosed this EEG as mild type of 
hypsarrhythmia. 
B: EEG before adding on lamotrigine 
(LTG) at 2 years and 11 months old. 
Diffuse polyspikes and polyspikes and 
wave were found. EEG finding was 
evolving into the finding of Lennox–
Gastaut syndrome.
C: EEG after adding LTG at 3 years and 5 
months old. The epileptic discharge 
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Figure 3. Clinical course of the present case.
PB, phenobarbital; VPA, valproic acid; ZNS, 
zonisamide; LTG, lamotrigine. 
Among OMIM genes within the deleted region, 12 genes (boldface type) were included in the TruSight 
One sequencing panel. 
Number 
of genes 
Gene symbol (OMIM number) 
Refseq 
genes 57 
PHLPP2, SNORA70D, AP1G1, SNORD71, ATXN1L, ZNF821, IST1, PKD1L3, 
DHODH, HP, HPR, TXNL4B, DHX38, PMFBP1, LINC01572, ZFHX3, HCCAT5, 
C16orf47, LINC01568, LOC101928035, PSMD7, LOC283922, NPIPB15, 
LOC105376772, CLEC18B, GLG1, RFWD3, MLKL, FA2H, WDR59, ZNRF1, LDHD, 
ZFP1, CTRB2, CTRB1, LOC100506281, BCAR1, CFDP1, TMEM170A, CHST6, 
CHST5, TMEM231, GABARAPL2, ADAT1, KARS, TERF2IP, DUXB, CNTNAP4, 




PHLPP2 (611066), AP1G1 (603533), ATXN1L (614301), IST1 (616434), PKD1L3 
(607895), DHODH (126064), HP (140100), HPR (140210), DHX38 (605584), ZFHX3 
(104155), HCCAT5 (615613), PSMD7 (157970), CLEC18B (616572), GLG1 (600753), 
RFWD3 (614151), MLKL (615153), FA2H (611026), WDR59 (617418), ZNRF1 
(612060), LDHD (607490), ZFP1 (617230), CTRB1 (118890), BCAR1 (602941), 
CFDP1 (608108), CHST6 (605294), CHST5 (604817), TMEM231 (614949), 
GABARAPL2 (607452), ADAT1 (604230), KARS (601421), TERF2IP (605061), 
CNTNAP4 (610518), MON1B (608954), ADAMTS18 (607512), NUDT7 (609231), 
CLEC3A (613588), WWOX (605131) 
Supplemental Table S1
